{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:06:49Z","timestamp":1780380409004,"version":"3.54.1"},"reference-count":57,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>Pain is a common complication of sickle cell disease. Sickle cell pain can often be effectively managed by pediatricians in outpatient and hospital settings. Acute pain management should be initiated quickly. Patients need to be evaluated for sickle cell complications and other causes of pain. Nonsteroidal anti-inflammatory drugs and opioids are the mainstay of pain treatment, but additional therapies include hydration, local pain control, muscle relaxants, and nonpharmacologic approaches. Healthy lifestyle habits and good behavioral and mental health are important for preventing and coping with sickle cell disease pain. Disease-modifying therapies, such as hydroxyurea, can help prevent sickle hemoglobin polymerization and acute pain episodes. Because sickle cell disease largely affects people who are racialized minorities in the United States, health-care providers need to be aware of how their own personal biases may affect care of these patients.<\/jats:p>","DOI":"10.1542\/pir.2022-005631","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T03:04:41Z","timestamp":1704078281000},"page":"26-38","source":"Crossref","is-referenced-by-count":6,"title":["Management of Acute Sickle Cell Disease Pain"],"prefix":"10.1542","volume":"45","author":[{"given":"Jason N.","family":"Payne","sequence":"first","affiliation":[{"name":"*Children\u2019s Healthcare of Atlanta, Atlanta, GA"},{"name":"\u2020Morehouse School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice E.","family":"Gee","sequence":"additional","affiliation":[{"name":"*Children\u2019s Healthcare of Atlanta, Atlanta, GA"},{"name":"\u2021Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"issue":"2","key":"2024012215463249800_B1","doi-asserted-by":"crossref","first-page":"e27535","DOI":"10.1002\/pbc.27535","article-title":"Pediatric residents\u2019 perceived barriers to opioid use in sickle cell disease pain management","volume":"66","author":"Fearon","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2024012215463249800_B2","doi-asserted-by":"crossref","first-page":"853835","DOI":"10.1155\/2015\/853835","article-title":"Attitudes toward management of sickle cell disease and its complications: a national survey of academic family physicians","volume":"2015","author":"Mainous","year":"2015","journal-title":"Anemia"},{"key":"2024012215463249800_B3","unstructured":"Centers for Disease Control and Prevention. Data & statistics on sickle cell disease. Available at: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html. Updated May 2, 2022"},{"issue":"20","key":"2024012215463249800_B4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJMp2022125","article-title":"When actions speak louder than words: racism and sickle cell disease","volume":"383","author":"Power-Hays","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2024012215463249800_B5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/pir.33.5.195","article-title":"Sickle cell disease","volume":"33","author":"McCavit","year":"2012","journal-title":"Pediatr Rev"},{"key":"2024012215463249800_B6","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.2147\/JPR.S185582","article-title":"Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management","volume":"11","author":"Uwaezuoke","year":"2018","journal-title":"J Pain Res"},{"issue":"12","key":"2024012215463249800_B7","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2024012215463249800_B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1054\/jpai.2002.128064","article-title":"Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports","volume":"3","author":"Dampier","year":"2002","journal-title":"J Pain"},{"issue":"5","key":"2024012215463249800_B9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"J Pain"},{"issue":"1","key":"2024012215463249800_B10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26758","article-title":"An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes","volume":"65","author":"Bou-Maroun","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2024012215463249800_B11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"2024012215463249800_B12","first-page":"836","article-title":"Indications for RBC exchange transfusion in patients with sickle cell disease: revisited","volume":"49","author":"Ballas","year":"2019","journal-title":"Ann Clin Lab Sci"},{"key":"2024012215463249800_B13","unstructured":"Rogers\u2008ZR, Morris\u2008CR. Evaluation and management of fever in children and adults with sickle cell disease. UpToDate. Available at: https:\/\/www.uptodate.com\/contents\/evaluation-and-management-of-fever-in-children-and-adults-with-sickle-cell-disease"},{"issue":"3","key":"2024012215463249800_B14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1542\/peds.109.3.526","article-title":"Health supervision for children with sickle cell disease","volume":"109","author":"Section on Hematology\/Oncology Committee on Genetics","year":"2002","journal-title":"Pediatrics"},{"issue":"3","key":"2024012215463249800_B15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1537-2995.2011.03321.x","article-title":"Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia","volume":"52","author":"Arndt","year":"2012","journal-title":"Transfusion"},{"issue":"1","key":"2024012215463249800_B16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2017.1.534","article-title":"Pain-measurement tools in sickle cell disease: where are we now?","volume":"2017","author":"Darbari","year":"2017","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"3","key":"2024012215463249800_B17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pain.2009.03.002","article-title":"Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children\u2019s self-reports of pain intensity","volume":"143","author":"von Baeyer","year":"2009","journal-title":"Pain"},{"issue":"2","key":"2024012215463249800_B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0304-3959(90)90018-9","article-title":"The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties","volume":"41","author":"Bieri","year":"1990","journal-title":"Pain"},{"key":"2024012215463249800_B19","unstructured":"International Association for the Study of Pain. Faces Pain Scale\u2013Revised. Available at: https:\/\/www.iasp-pain.org\/resources\/faces-pain-scale-revised\/"},{"issue":"12","key":"2024012215463249800_B20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jpain.2014.09.008","article-title":"Development and validation of the Youth Acute Pain Functional Ability Questionnaire (YAPFAQ)","volume":"15","author":"Zempsky","year":"2014","journal-title":"J Pain"},{"issue":"5","key":"2024012215463249800_B21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bja.2021.11.032","article-title":"Utility of unidimensional and functional pain assessment tools in adult postoperative patients: a systematic review","volume":"128","author":"Baamer","year":"2022","journal-title":"Br J Anaesth"},{"key":"2024012215463249800_B22","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2019-124847","article-title":"A pilot study of a functional pain assessment for adult patients admitted with sickle cell pain crisis","volume":"134","author":"Nelson","year":"2019","journal-title":"Blood"},{"issue":"10232","key":"2024012215463249800_B23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(20)30893-X","article-title":"COVID-19 exacerbating inequalities in the US","volume":"395","author":"Dorn","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"2024012215463249800_B24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpain.2011.10.014","article-title":"The perception of pain in others: how gender, race, and age influence pain expectations","volume":"13","author":"Wandner","year":"2012","journal-title":"J Pain"},{"issue":"16","key":"2024012215463249800_B25","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1073\/pnas.1516047113","article-title":"Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites","volume":"113","author":"Hoffman","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024012215463249800_B26","unstructured":"American Medical Association and Association of American Medical Colleges. Advancing health equity: guide on language, narrative and concepts. Available at: https:\/\/ama-assn.org\/equity-guide. Accessed July 2022"},{"issue":"8","key":"2024012215463249800_B27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/01612840.2018.1443530","article-title":"Stigma of sickle cell disease: a systematic review","volume":"39","author":"Bulgin","year":"2018","journal-title":"Issues Ment Health Nurs"},{"key":"2024012215463249800_B28","article-title":"WHO analgesic ladder","volume-title":"StatPearls [Internet]","author":"Anekar","year":"2022"},{"key":"2024012215463249800_B29","author":"Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online"},{"issue":"5","key":"2024012215463249800_B30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jen.2021.05.007","article-title":"System level informatics to improve triage practices for sickle cell disease vaso-occlusive crisis: a cluster randomized controlled trial","volume":"47","author":"Linton","year":"2021","journal-title":"J Emerg Nurs"},{"issue":"1","key":"2024012215463249800_B31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/asheducation-2017.1.412","article-title":"Improving emergency department-based care of sickle cell pain","volume":"2017","author":"Glassberg","year":"2017","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"6","key":"2024012215463249800_B32","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26332","article-title":"Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease","volume":"64","author":"Fein","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2024012215463249800_B33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation-2007.1.97","article-title":"Current issues in sickle cell pain and its management","volume":"2007","author":"Ballas","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"5","key":"2024012215463249800_B34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/pbc.20403","article-title":"Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome","volume":"45","author":"Buchanan","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2024012215463249800_B35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26742","article-title":"Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: a single institution experience","volume":"65","author":"Carden","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2024012215463249800_B36","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12353","article-title":"Normal saline is associated with increased sickle red cell stiffness and prolonged transit times in a microfluidic model of the capillary system","volume":"24","author":"Carden","year":"2017","journal-title":"Microcirculation"},{"issue":"12","key":"2024012215463249800_B37","doi-asserted-by":"crossref","first-page":"e27420","DOI":"10.1002\/pbc.27420","article-title":"Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis","volume":"65","author":"Payne","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024012215463249800_B38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hoc.2018.01.014","article-title":"Key components of pain management for children and adults with sickle cell disease","volume":"32","author":"Brandow","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2024012215463249800_B39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.pec.0000106235.72265.29","article-title":"Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department","volume":"20","author":"Melzer-Lange","year":"2004","journal-title":"Pediatr Emerg Care"},{"issue":"8","key":"2024012215463249800_B40","doi-asserted-by":"crossref","first-page":"e29665","DOI":"10.1002\/pbc.29665","article-title":"Demand-only patient-controlled analgesia for treatment of acute vaso-occlusive pain in sickle cell disease","volume":"69","author":"Carullo","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2024012215463249800_B41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/SPC.0000000000000437","article-title":"Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease","volume":"13","author":"Puri","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"key":"2024012215463249800_B42","unstructured":"Centers for Disease Control and Prevention. Living well with sickle cell disease. Available at: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/healthyliving-living-well.html"},{"key":"2024012215463249800_B43","unstructured":"National Institutes of Health - National Heart Lung, and Blood Institute. Sickle cell disease: tips for healthy living fact sheet. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/all-publications-and-resources\/sickle-cell-disease-tips-healthy-living"},{"key":"2024012215463249800_B44","unstructured":"National Center for Complementary and Integrative Health. Pain: Considering Complementary Approaches (eBook). National Institutes of Health. Available at: https:\/\/www.nccih.nih.gov\/health\/pain-considering-complementary-approaches-ebook. 2019"},{"key":"2024012215463249800_B45","unstructured":"National Center for Complementary and Integrative Health. Strategic plan FY 2021-2025: mapping a pathway to research on whole person health. National Institutes of Health. Available at: https:\/\/www.nccih.nih.gov\/about\/nccih-strategic-plan-2021-2025"},{"issue":"2","key":"2024012215463249800_B46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pbc.24178","article-title":"Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children","volume":"59","author":"Strouse","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024012215463249800_B47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2024012215463249800_B48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2024012215463249800_B49","first-page":"873","article-title":"Voxelotor: a hemoglobin S polymerization inhibitor for the treatment of sickle cell disease","volume":"11","author":"Yenamandra","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"2024012215463249800_B50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17474086.2022.2031967","article-title":"Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis","volume":"15","author":"Shah","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2024012215463249800_B51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/can.2019.0036","article-title":"Daily cannabis users with sickle cell disease show fewer admissions than others with similar pain complaints","volume":"5","author":"Curtis","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"2024012215463249800_B52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/can.2017.0011","article-title":"The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to vaso-occlusive crises","volume":"2","author":"Ballas","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"issue":"7","key":"2024012215463249800_B53","doi-asserted-by":"crossref","first-page":"e2010874","DOI":"10.1001\/jamanetworkopen.2020.10874","article-title":"Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial","volume":"3","author":"Abrams","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024012215463249800_B54","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1002\/emp2.12770","article-title":"Marijuana use in children: an update focusing on pediatric tetrahydrocannabinol and cannabidiol use","volume":"3","author":"Stoner","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"10","key":"2024012215463249800_B55","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"issue":"3","key":"2024012215463249800_B56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/jcm10030438","article-title":"Opioids and sickle cell disease: from opium to the opioid epidemic","volume":"10","author":"Ballas","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"2024012215463249800_B57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"}],"container-title":["Pediatrics in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article-pdf\/45\/1\/26\/1592427\/pedsinreview.2022005631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article-pdf\/45\/1\/26\/1592427\/pedsinreview.2022005631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:47:01Z","timestamp":1705938421000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article\/45\/1\/26\/196227\/Management-of-Acute-Sickle-Cell-Disease-Pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/pir.2022-005631","relation":{},"ISSN":["0191-9601","1526-3347"],"issn-type":[{"value":"0191-9601","type":"print"},{"value":"1526-3347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}